标准治疗中伊德基奥仑赛与西达基奥仑赛治疗复发/难治多发性骨髓瘤的比较
该回顾性图表综述纳入19家机构截至2022年12月31日采集淋巴细胞且拟接受标准治疗伊德基奥仑赛或西达基奥仑赛的复发/难治多发性骨髓瘤患者,采用逆概率治疗加权比较两组结局。西达基奥仑赛组疗效和生存更优,但≥3级细胞因子释放综合征、感染、第二原发恶性肿瘤和迟发性神经毒性的发生风险更高。
要点
- 西达基奥仑赛组≥完全缓解率更高(OR 2.42),无进展生存(HR 0.48)和总生存(HR 0.67)更优。
- 西达基奥仑赛组≥3级细胞因子释放综合征(OR 6.80)、感染(OR 2.03)和迟发性神经毒性(OR 20.07)风险更高。
- 两组免疫效应细胞相关神经毒性综合征、任何细胞因子释放综合征、第30天和第90天严重血细胞减少及非复发死亡无显著差异。
核心结论
- 与伊德基奥仑赛相比,西达基奥仑赛显示出更优的疗效和生存,但某些毒性的发生率更高。
研究设计与样本
- 回顾性图表综述,数据来自19家机构截至2022年12月31日采集淋巴细胞且拟接受标准治疗伊德基奥仑赛或西达基奥仑赛的复发/难治多发性骨髓瘤患者。
- 共641例患者采集淋巴细胞(伊德基奥仑赛n=386,西达基奥仑赛n=255),其中586例回输(伊德基奥仑赛n=350,西达基奥仑赛n=236)。
- 采用逆概率治疗加权(IPTW)比较两种治疗类型的结局。
主要发现
- 伊德基奥仑赛组中位随访12.6个月,西达基奥仑赛组中位随访13.0个月。
- 逆概率治疗加权后患者特征均衡。
- 西达基奥仑赛与更高的≥3级细胞因子释放综合征风险相关(OR 6.80,95%CI 2.28至20.33)。
- 西达基奥仑赛与更高的感染风险相关(OR 2.03,95%CI 1.41至2.92)。
- 西达基奥仑赛与更高的第二原发恶性肿瘤风险相关(OR 1.77,95%CI 0.89至3.56)。
关键数值与推荐
- 西达基奥仑赛与更好的治疗反应相关(≥完全缓解:OR 2.42,95%CI 1.63至3.60)。
- 西达基奥仑赛与更长的无进展生存相关(HR 0.48,95%CI 0.36至0.63)。
- 西达基奥仑赛与更长的总生存相关(HR 0.67,95%CI 0.46至0.97)。
- 治疗类型与免疫效应细胞相关神经毒性综合征、任何细胞因子释放综合征、第30天和第90天严重血细胞减少或非复发死亡之间未观察到关联。
- 将伊德基奥仑赛队列限制在与西达基奥仑赛获美国食品药品监督管理局批准同期(≥2022年3月)回输的患者中重复分析,观察到一致的结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, and survival among patients with RRMM treated with standard-of-care (SOC) ide-cel or cilta-cel. METHODS: Data were from a retrospective chart review of patients with RRMM leukapheresed by December 31, 2022, with the intent to receive SOC ide-cel or cilta-cel at 19 institutions. An inverse probability of treatment weighting (IPTW) approach was used to compare outcomes by therapy type. RESULTS: A total of 641 patients were leukapheresed by December 31, 2022, with ide-cel (n = 386) and cilta-cel (n = 255). Five hundred eighty-six patients were infused (n = 350 for ide-cel; n = 236 for cilta-cel) with a median follow-up of 12.6 and 13.0 months for ide-cel and cilta-cel, respectively. After IPTW, patient characteristics were well balanced. Cilta-cel was associated with higher likelihood of grade ≥3 cytokine release syndrome (CRS; odds ratio [OR], 6.80 [95% CI, 2.28 to 20.33]), infections (OR, 2.03 [95% CI, 1.41 to 2.92]), second primary malignancies (OR, 1.77 [95% CI, 0.89 to 3.56]), and delayed neurotoxicity (OR, 20.07 [95% CI, 4.46 to 90.20]). Cilta-cel was also associated with better treatment responses (≥complete response: OR, 2.42 [95% CI, 1.63 to 3.60]), longer progression-free survival (hazard ratio [HR], 0.48 [95% CI, 0.36 to 0.63]), and longer overall survival (HR, 0.67 [95% CI, 0.46 to 0.97]). No associations were observed between therapy type and immune effector cell-associated neurotoxicity syndrome, any CRS, severe cytopenia at days 30 and 90, or nonrelapse mortality. We observed consistent findings when repeating the analyses restricting the ide-cel cohort to patients infused during the same time period as Food and Drug Administration approval for cilta-cel (≥March 2022). CONCLUSION: Cilta-cel demonstrated superior efficacy and survival, with higher incidence of certain toxicities, compared with ide-cel.
引用
- Hansen DK, Peres LC, Dima D, et al. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025. PMID: 39965175. doi:10.1200/JCO-24-01730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。